Abstract: This paper is looking at the trends of future medicine focusing on IBM Watson, Microsoft Intelligent Network for Eye care (MINE), and Google's AI Eye Doctor. Microsoft's Mine, an artificial intelligence assistant program, and Google's Eye Doctor, were created because of the two characteristics of eye disease. The disease of the eye significantly reduces the quality of human life, but it can be prevented if the illness is discovered in advance. Therefore, prevention of these diseases is important. Through the development of the Google eye Doctor Program shown in the article of "Retinopathy Algorithm", we obtained the implications for the ethical guidelines that can be applied to other artificial intelligence development programs. At the heart of these guidelines is the efficient and safe treatment of patient illnesses for medical purposes.
Introduction


Artificial intelligence is divided into strong and weak. Stronger is the Terminator T-1000, which appears in the film "Ultron" in the movie "Avengers: Age of Ultron" or in the movie "Terminator Genisys". And in the movie "Prometheus", there are artificial intelligence robots such as David. Weakness is Jarvis in Iron Man. The recently developed IBM Watson is a weak artificial intelligence. This can be called the CDSS (Clinical Decision Support System) program. IBM Watson is especially well received in Korea. IBM Watson summarizes the papers that doctors should look at in relation to the patient's illness, and it is equipped with the function to display the latest medical information. In addition, the most appropriate treatment for patients is presented using up-to-date latest medical information. In this way, CDSS is helping doctors. In this paper, I will examine IMB Watson, Microsoft Intelligent Network for Eye care (MINE), and Google's AI Eye Doctor, which are currently developed artificial intelligence programs. IBM Watson is currently the most famous CDSS in the world. In particular, IBM Watson for oncology was introduced in Korea. In particular, we will look at the artificial intelligence assistant programs (CDSS for ophthalmology) created through strategic alliances with Indian hospitals. Microsoft has Mine, and Google has Eye Doctor. Ophthalmologists often use imaging to diagnose a specific disease rather than other diseases. And blindness significantly reduces the quality of human life, so prevention is more important than anything else. It seems that two characteristics of these ophthalmologic diseases have met and artificial intelligence ophthalmologist program has been made. In particular, the Google eye doctor has already published a paper entitled "Development and 
Present Status of Clinical Decision Support System (CDSS) and Proposal of Ethical Guideline for Artificial Intelligence Development in Medical Field
154
(Retinopathy Algorithm)." It is medically proven. I believe that through the development of the Google Eye Doctor program in the retinopathy algorithm, I can get implications for ethical guidelines that can be applied to other artificial intelligence development programs. Next, I propose ethical guidelines for artificial intelligence development and production through this process. At the heart of these guidelines is the efficient and safe treatment of patient illnesses for medical purposes. Next, we look at how artificial intelligence can help physicians in future medicine.
Status of International CDSS Development
IBM Watson [1]
In Korea, the cancer diagnosis "Waton for Oncology" was introduced at Gil Medical Center in Incheon [2] . In addition, seven hospitals including Daegu Catholic University Hospital, Keimyung University Dongsan Hospital, Gunyang University Hospital, Chosun University Hospital and Chonnam University Hospital introduced Watson [3] . In December 2017, a consensus rate of 56% was announced at the 1st anniversary symposium of the Gachon University Gil Hospital in Korea. The rate of agreement was 91%~100% in five cancers. Although it is described as a difference according to the racial characteristic, there is opinion that the performance is exaggerated such as using training data for verification from the beginning. The Food and Drug Administration classified Watson as a "non-medical device" at the end of 2017 when it released the guidelines for approval and examination of medical devices with big data and artificial intelligence technologies. 
MS Mine (Microsoft
Google's AI Eye Doctor
Diabetic retinopathy patients are approximately 28.5% in the US and 18% in India. In most guidelines, people without retinopathy or mild diabetic retinopathy should be repeatedly screened for diabetic retinopathy for 6 months. Clinically significant macular edema, known as severe or malignant diabetic retinopathy or diabetic macular edema, should be treated by an ophthalmologist for evaluation of treatment within weeks to months. And the target diabetic retinopathy should be screened annually and managed every four years when diabetic retinopathy is considered moderate or worsening. At this time, retinal imaging is a widely used test tool for diabetic retinopathy. India has a lack of ophthalmologists. These circumstances have led many Indians to receive We describe the process of developing an algorithm for the diagnosis of macular edema and its application. In this paper, the authors used a computerized multiple convolutional neural network to train AI with diabetic retinopathy using 12,875 retinas, and the results are presented to 54 American licensors from May to December 2015. The algorithm was verified using two datasets for each of January and February 2014. As a result, the sensitivity and specificity of the algorithm for detecting RDR (referable diabetic retinopathy) defined as moderate and diabetic retinopathy, were similar to those of ophthalmologist. The algorithm was evaluated through two selected operating points in the development set. One point is selected for high specificity and the other is selected for high sensitivity. The results of this paper are as follows.
The Using the first operating cut point with high specificity, for EyePACS-1, the sensitivity was 90.3% (95% CI, 87.5%-92.7%) and the specificity was 98.1% (95% CI, 97.8%-98.5%). For Messidor-2, the sensitivity was 87.0% (95% CI, 81.1%-91.0%) and the specificity was 98.5% (95% CI, 97.7%-99.1%). Using a second operating point with high sensitivity in the development set, for EyePACS-1 the sensitivity was 97.5% and specificity was 93.4% and for Messidor-2 the sensitivity was 96.1% and specificity was 93.9% [7] .
As noted above, the authors of this paper finds that algorithms based on deep-learning learning show high sensitivity and specificity for detecting diabetic retinopathy. However, the authors suggest that further study is needed to determine the feasibility of applying this algorithm in clinical settings and to determine whether the use of algorithms can lead to improved therapies and outcomes compared to current ophthalmic assessments do. However, in the current situation, the authors suggest that Google Eye Doctor can reduce the access barriers of patients who have difficulty accessing medical care, and can protect patients' health through early detection and treatment of disease.
Proposal of Ethical Guidelines for the Development and Production of International CDSS
I think the development of Google's Ophthalmic CDSS through the alliance between Aravind Hospital in India and the US IBM is very exemplary. I emphasis on "Artificial Intelligence and Healthcare Resource Allocation" [8] the distribution of surplus resources and medical resources from artificial intelligence in the thesis of emphasizes the priority distribution of environment and irrational practices in labor-intensive medical field, and the priority distribution of patient-centered medical environment. The paper "The Retinopathy Algorithm" shows how advanced country skills and data from underdeveloped countries can be combined to work for patients who are the least beneficiaries of inadequate medical care in India. The development of CDSS due to this technical cooperation is expected to continue. I would like to elaborate the ethical guidelines for the development of future artificial intelligence program CDSS, as shown in the paper "Retinopathy Algorithm".
Ethical Guidelines for the Purpose of International CDSS Development and Production: Minimum Beneficiary Priority Supply-Priority to Where There Is No or Insufficient Doctors and Doctors Do Not Work
I believe that the development of Ophthalmic CDSS in India's Aravind Hospital and Google has been justified as a special medical environment in India. Aravind Hospital in India seems to have planned this project for patients who are in blindness but do not receive ophthalmologic care. Due to the development of Ophthalmic CDSS, patients without blindness who live in areas without ophthalmologist have relatively easy access to ophthalmology. Because of this project, the benefits of developing Ophthalmic CDSS are the first to return to those who receive the least benefit. Google's Ophthalmic CDSS is a very good example of how to improve patient health through early detection and treatment of disease. In the future, we should continue to work together for the least beneficiaries by meeting the knowledge of advanced countries and the information of the developed countries for those who have no doctors or do not have money in very few places and have diseases.
Ethical Guidelines for Acquisition and Management of International CDSS Data
Obtaining Legitimate Data-Securing Consent through Safe Harbor and Legitimacy through IRB (Institutional Review Board) Passing
The data used in the Retinopathy Algorithm retrospectively retrieved the macular center retina from the EyePACS of the United States and the Aravind Eye Hospital of India (Sankara Nethralaya, Narayana Nethralaya) to develop a data set algorithm. At this time, all images were not identified according to the Safe Harbor before transferring to the investigators. And this project has passed the IRB of each institution. Obtaining such legitimate data require the anonymization of the information to be secured and the approval of the Institutional Bioethics Committee. In the securing of data, the identification, management and supervision of the Institutional Bioethics Committee on the non-identification and anonymization measures of personal information and its research process and research results are required. Fifty-four US-licensed resident ophthalmologists and 54 ophthalmologists who participated in Google's Ophthalmic CDSS graded 20 to 62,508 images (mean: 9,774; median: 2,021) for each individual. Three of these trainees scored over 1,000 images. However, these three trainees did not lag behind in the evaluation of licensed ophthalmologists. The reliability of the mediator was measured for each physician using a pair of comparisons, and the number of classes matched the other graders that exceeded the total number of pairs I believe that in the development of any kind of CDSS, professional labor must be put in place for data validation. In some authoritarian cultures, medical practitioners, such as interns and residents, may put CDSS-validated labor under the name "education" and not pay for labor. Therefore, when submitting the CDSS research plan to the Institutional Bioethics Committee, an item of labor cost for algorithm verification labor should be submitted.
Establishing a Data Sharing Plan-Sharing Secured Medical Data
Google's Ophthalmic CDSS algorithm was trained to identify only diabetic retinopathy and diabetic macular edema, and there was no training to identify it in the presence of non-diabetic retinopathy. Therefore, this case can be missed. In the paper Retinopathy Algorithm, the authors believe that Google's Ophthalmic CDSS algorithm does not replace a comprehensive visual acuity test with many factors such as visual acuity, refractive, slit lamp, and intraocular pressure measurements. The authors of this paper propose two preconditions for developing a similar high performance algorithm for medical imaging using computer deep learning based on this study. First, there should be more data. In other words, there must be a large development kit with tens of thousands of unusual cases. Second, more diverse data must be secured so that various diseases can be diagnosed. Thus, securing of data is the key to any CDSS. Therefore, for future medical care, sharing of data and in-depth management of medical data secured for such sharing is required. 
International CDSS Ethical Guidelines for
Conclusion
In this paper, I propose the following ethical guidelines for the development and production of artificial intelligence: (1) establish standards for data standardization, (2) formulate data, (3) secure legitimate data, (4) provide reasonable labor cost for labor verification for algorithm verification; (5) provide minimum beneficiary priority supply; (6) provide priority to places where physicians are not available and doctors are not able to do; (7) provide data sharing plans; (8) secure shared medical data; (9) the establishment of research plans and the securing of resources; (10) planning and financing for algorithm refinements. Artificial intelligence programs already developed should be supplemented and modified. In addition to ophthalmology, artificial intelligence will be developed for a number of other diseases. I emphasized that it is important that the six propositions proposed in this paper are more important than the development of assistive programs for patients and physicians. I can think of the criticism that the technology of developed countries exploits the information of the backward countries about this proposal of the writer.
I think trust is the most important thing in medicine.
I believe that as for trust between individuals and society, the development of any artificial intelligence program that does not presuppose such a culture of trust will lead to many misunderstandings and end up in a form of misfortune in which the least beneficiaries do not receive the appropriate benefits. At this time, people without money and ignorance will not know that they will not benefit even though they can benefit. All of this will happen because of the culture of trust. Instead of this invisible tragedy, I hope that we can unfold the courage to do what our civilization can do based on a culture of trust.
